137 related articles for article (PubMed ID: 12460413)
21. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis.
Utsumi K; Kawabe M; Hirama A; Ueda K; Kamada Y; Arii K; Komaba Y; Katsura K; Iino Y; Katayama Y
Clin Chim Acta; 2007 Feb; 377(1-2):198-200. PubMed ID: 17126824
[TBL] [Abstract][Full Text] [Related]
22. Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits.
Yamamoto T; Yamashita T
Ther Apher; 1998 Feb; 2(1):25-30. PubMed ID: 10227785
[TBL] [Abstract][Full Text] [Related]
23. [Arteriosclerosis obliterans that was improved by LDL apheresis].
Suzuki H; Mutoh E; Kitagawa T; Kubota H; Takasugi Y
Hokkaido Igaku Zasshi; 1993 Jan; 68(1):126-31. PubMed ID: 8444401
[TBL] [Abstract][Full Text] [Related]
24. Coronary artery disease in 100 diabetics with end-stage renal failure.
Braun WE; Phillips DF; Vidt DG; Novick AC; Nakamoto S; Popowniak KL; Paganini E; Magnusson M; Pohl M; Steinmuller DR
Transplant Proc; 1984 Jun; 16(3):603-7. PubMed ID: 6375027
[No Abstract] [Full Text] [Related]
25. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans.
Uno H; Ueki Y; Murashima J; Miyake S; Tominaga Y; Eguchi K; Yano K
Atherosclerosis; 1995 Jul; 116(1):93-102. PubMed ID: 7488336
[TBL] [Abstract][Full Text] [Related]
26. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients.
Tsurumi-Ikeya Y; Tamura K; Azuma K; Mitsuhashi H; Wakui H; Nakazawa I; Sugano T; Mochida Y; Ebina T; Hirawa N; Toya Y; Uchino K; Umemura S
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):1058-65. PubMed ID: 20203302
[TBL] [Abstract][Full Text] [Related]
27. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy.
Nakamura T; Kawagoe Y; Ogawa H; Ueda Y; Hara M; Shimada N; Ebihara I; Koide H
Am J Kidney Dis; 2005 Jan; 45(1):48-53. PubMed ID: 15696443
[TBL] [Abstract][Full Text] [Related]
28. Diabetic nephropathy and risk factors for peripheral artery disease in Chinese with type 2 diabetes mellitus.
Hsieh MC; Tien KJ; Perng DS; Hsiao JY; Chang SJ; Liang HT; Chen HC; Tu ST
Metabolism; 2009 Apr; 58(4):504-9. PubMed ID: 19303971
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effect of aggressive low-density lipoprotein apheresis in a familial hypercholesterolemic patient with severe diabetic scleredema.
Koga N
Ther Apher; 2001 Dec; 5(6):506-12. PubMed ID: 11800090
[TBL] [Abstract][Full Text] [Related]
30. One year experience with a low density lipoprotein apheresis system.
Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
[TBL] [Abstract][Full Text] [Related]
31. Heparin-mediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion.
Blessing FJ; Jaeger B; Wang Y; Walli AK; Seidel D
Thromb Res; 2005; 115(1-2):39-43. PubMed ID: 15567451
[TBL] [Abstract][Full Text] [Related]
32. LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis.
Sato E; Amaha M; Nomura M; Matsumura D; Ueda Y; Nakamura T
Diabetes Res Clin Pract; 2014 Nov; 106(2):241-6. PubMed ID: 25306260
[TBL] [Abstract][Full Text] [Related]
33. LDL-apheresis dramatically improves generalized calciphylaxis in a patient undergoing hemodialysis.
Iwagami M; Mochida Y; Ishioka K; Oka M; Moriya H; Ohtake T; Hidaka S; Kobayashi S
Clin Nephrol; 2014 Mar; 81(3):198-202. PubMed ID: 23036228
[TBL] [Abstract][Full Text] [Related]
34. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure.
Bosch T; Thiery J; Gurland HJ; Seidel D
Nephrol Dial Transplant; 1993; 8(12):1350-8. PubMed ID: 8159304
[TBL] [Abstract][Full Text] [Related]
36. Long-term (14 years) effect of LDL apheresis on obstructive changes in aortocoronary saphenous-vein bypass grafts in a case of heterozygous familial hypercholesterolemia with the LDL receptor proline664 to leucine mutation.
Takahashi K; Kobayashi J; Bujo H; Takahashi M; Taira K; Kaneko K; Tashiro J; Shinomiya M; Miyazaki A; Saito Y
Intern Med; 2000 Oct; 39(10):804-9. PubMed ID: 11030204
[TBL] [Abstract][Full Text] [Related]
37. Vascular complications of the lower extremities in diabetic patients on peritoneal dialysis.
Pliakogiannis T; Bailey S; Cherukuri S; Taskapan H; Ahmad M; Oliver T; Bargman JM; Oreopoulos DG
Clin Nephrol; 2008 May; 69(5):361-7. PubMed ID: 18538099
[TBL] [Abstract][Full Text] [Related]
38. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis.
Sokunbi DO; Wadhwa NK; Suh H
Adv Perit Dial; 1994; 10():77-80. PubMed ID: 7999869
[TBL] [Abstract][Full Text] [Related]
39. Significant coronary artery disease appears to have increased in the past 21 years in diabetics being evaluated for organ transplantation.
Braun WE
Transplantation; 2005 Dec; 80(11):1637-8. PubMed ID: 16371939
[No Abstract] [Full Text] [Related]
40. LDL-Apheresis for diabetic nephropathy: a possible new tool.
Kobayashi S
Nephron; 1998 Aug; 79(4):505-6. PubMed ID: 9689183
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
